Cargando…
A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses
Cancer therapy targets malignant cells that are surrounded by a diverse complement of nonmalignant stromal cells. Therapy-induced damage of normal cells can alter the tumor microenvironment, causing cellular senescence and activating cancer-promoting inflammation. However, how these damage responses...
Autores principales: | Bent, Eric H., Gilbert, Luke A., Hemann, Michael T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024680/ https://www.ncbi.nlm.nih.gov/pubmed/27566778 http://dx.doi.org/10.1101/gad.284851.116 |
Ejemplares similares
-
mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype
por: Herranz, Nicolás, et al.
Publicado: (2015) -
The PI3K/Akt/mTOR Pathway Is Implicated in the Premature Senescence of Primary Human Endothelial Cells Exposed to Chronic Radiation
por: Yentrapalli, Ramesh, et al.
Publicado: (2013) -
PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011) -
Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014) -
PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)